U.S. Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trends Analysis Report By Service (Upstream, Downstream, Fill/Finish), By Source (Mammalian, Non-mammalian), By Product (Biologics, Biosimilar), And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Research Methodology And Scope
                   1.1. Market Segmentation & Scope
                       1.1.1. Segment Definitions
                       1.1.2. Source
                       1.1.3. Service
                       1.1.4. Products
                   1.2. Estimates And Forecast Timeline
                   1.3. Objectives
                       1.3.1. Objective - 1
                       1.3.2. Objective - 2
                       1.3.3. Objective - 3
                   1.4. Research Methodology
                   1.5. Information Procurement
                       1.5.1. Purchased Database
                       1.5.2. GVR’s Internal Database
                       1.5.3. Secondary Sources
                       1.5.4. Primary Research
                   1.6. Information Or Data Analysis
                       1.6.1. Data Analysis Models
                   1.7. Market Formulation & Validation
                   1.8. Model Details
                       1.8.1. Commodity Flow Analysis
                       1.8.2. Parent Market Analysis
                   1.9. List Of Secondary Sources
                   1.10. List Of Abbreviations
Chapter 2. Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                   2.3. Competitive Insights
Chapter 3. Biopharmaceutical Contract Manufacturing Market Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Rise In Investment by CMOs For Capacity Expansion
                           3.2.1.2. Commercial Success of Biopharmaceuticals And Consequent Increase In Demand For Biopharmaceuticals
                           3.2.1.3. Robust Biopharmaceuticals Pipeline
                           3.2.1.4. Cost And Time Saving Benefits Offered by Contract Services
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Limited Outsourcing Amongst Well-Established Biopharmaceutical Manufacturers
                   3.3. Biopharmaceutical Contract Manufacturing Market Analysis Tools
                   3.4. Opportunity analysis
                       3.4.1. Expansion of fill-and-finish CMOs
                       3.4.2. Emergence of single-use bioprocessing equipment & solutions
                       3.4.3. Funding & investments
                   3.5. Trend Analysis
                       3.3.1 Merger & acquisitions in CMO industry
                       3.3.2 Trading of CMOs at strong EV/EBITDA multiples
                       3.3.3 Current trends in biopharmaceutical industry
                   3.6 Pipeline Analysis
                       3.6.1 Distribution of products & projects in development stage by clinical phase
                           3.6.1.1 Key finding of the analysis:
                       3.6.2 Pricing Analysis for Process Development
                       3.6.3 Biopharmaceuticals Contract Manufacturing Market -Swot Analysis, By Factor (Political & Legal, Economic and Technological)
                       3.6.4 Industry Analysis - Porter’s Five Forces
                       3.6.5 Customer Relationship Management in Contract Manufacturing
                       3.6.6 Selection process of CMO
                       3.6.7 Operations and quality oversight of CMOs
Chapter 4. U.S. Biopharmaceutical Contract Manufacturing Market: Source Estimates & Trend Analysis
                   4.1. Biopharmaceutical Contract Manufacturing Market, By Source: Segment Dashboard
                   4.2. Biopharmaceutical Contract Manufacturing Market, By Source: Movement Analysis
                   4.3. Biopharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Source, 2018 - 2030
                       4.3.1. Mammalian
                           4.3.1.1. Mammalian Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
                       4.3.2. Non-mammalian
                           4.3.2.1. Non-mammalian Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
Chapter 5. U.S. Biopharmaceutical Contract Manufacturing Market: Service Estimates & Trend Analysis
                   5.1. Biopharmaceutical Contract Manufacturing Market, By Service: Segment Dashboard
                   5.2. Biopharmaceutical Contract Manufacturing Market, By Service: Movement Analysis
                   5.3. Biopharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Service, 2018 - 2030
                       5.3.1. Process Development
                           5.3.1.1. Process Development Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
                           5.3.1.2. Downstream
                               5.3.1.2.1. Downstream Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
                           5.3.1.3. Upstream
                               5.3.1.3.1. Upstream Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
                       5.3.2. Fill & Finish Operations
                           5.3.2.1. Fill & Finish Operations Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
                       5.3.3. Analytical & QC studies
                           5.3.3.1. Analytical & QC studies Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
                       5.3.4. Packaging
                           5.3.4.1. Packaging Biopharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
Chapter 6. U.S. Biopharmaceutical Contract Manufacturing Market: Product Estimates & Trend Analysis
                   6.1. Biopharmaceutical Contract Manufacturing Market, By Product: Segment Dashboard
                   6.2. Biopharmaceutical Contract Manufacturing Market, By Product: Movement Analysis
                   6.3. Biopharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Products, 2018 - 2030
                       6.3.1. Biologics
                           6.3.1.1. Biologics Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
                           6.3.1.2. Monoclonal antibodies (MABs)
                               6.3.1.2.1. Monoclonal antibodies (MABs) Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
                           6.3.1.3. Recombinant Proteins
                               6.3.1.3.1. Recombinant Proteins Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
                           6.3.1.4. Vaccines
                               6.3.1.4.1. Vaccines Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
                           6.3.1.5. Antisense, RNAi, & Molecular Therapy
                               6.3.1.5.1. Antisense RNAi, & Molecular Therapy Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
                           6.3.1.6. Others
                               6.3.1.6.1. Others Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
                       6.3.2. Biosimilar
                           6.3.2.1. Biosimilar Biopharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Market Participant Categorization
                       7.1.1. Innovators
                       7.1.2. Market Leaders
                       7.1.3. Emerging Players
                       7.1.4. Company Market Share Analysis, 2022
                   7.2. Company Profiles
                       7.2.1. Boehringer Ingelheim International GmbH
                           7.2.1.1. Company Overview
                           7.2.1.2. Financial Performance
                           7.2.1.3. Service Benchmarking
                           7.2.1.4. Strategic Initiatives
                       7.2.2. Lonza
                           7.2.2.1. Company Overview
                           7.2.2.2. Financial Performance
                           7.2.2.3. Service Benchmarking
                           7.2.2.4. Strategic Initiatives
                       7.2.3. Rentschler Biopharma SE
                           7.2.3.1. Company Overview
                           7.2.3.2. Financial Performance
                           7.2.3.3. Service Benchmarking
                           7.2.3.4. Strategic Initiatives
                       7.2.4. AGC Biologics
                           7.2.4.1. Company Overview
                           7.2.4.2. Financial Performance
                           7.2.4.3. Service Benchmarking
                           7.2.4.4. Strategic Initiatives
                       7.2.5. ProBioGen AG
                           7.2.5.1. Company Overview
                           7.2.5.2. Financial Performance
                           7.2.5.3. Service Benchmarking
                           7.2.5.4. Strategic Initiatives
                       7.2.6. Samsung Biologics
                           7.2.6.1. Company Overview
                           7.2.6.2. Financial Performance
                           7.2.6.3. Service Benchmarking
                           7.2.6.4. Strategic Initiatives
                       7.2.7. Thermo Fisher Scientific Inc.
                           7.2.7.1. Company Overview
                           7.2.7.2. Financial Performance
                           7.2.7.3. Service Benchmarking
                           7.2.7.4. Strategic Initiatives
                       7.2.8. Wuxi Biologics
                           7.2.8.1. Company Overview
                           7.2.8.2. Financial Performance
                           7.2.8.3. Service Benchmarking
                           7.2.8.4. Strategic Initiatives
                       7.2.9. AbbVie Inc.
                           7.2.9.1. Company Overview
                           7.2.9.2. Financial Performance
                           7.2.9.3. Service Benchmarking
                           7.2.9.4. Strategic Initiatives
                       7.2.10. Siegfried Holding AG
                           7.2.10.1. Company Overview
                           7.2.10.2. Financial Performance
                           7.2.10.3. Service Benchmarking
                           7.2.10.4. Strategic Initiatives
Chapter 8. Kol Commentary/Recommendations

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 U.S. Biopharmaceuticals Contract Manufacturing Market, by Source, 2018 - 2030 (USD Million)
TABLE 4 U.S. Biopharmaceuticals Contract Manufacturing Market, by Service, 2018 - 2030 (USD Million)
TABLE 5 U.S. Biopharmaceuticals Contract Manufacturing Market, by Product, 2018 - 2030 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Cumulative success rate comparison of biologics with small molecules over time
FIG. 12 Number of biologics investigational new drugs, 2022
FIG. 13 Number of reference products by U.S. biosimilars launchable dates
FIG. 14 Market restraint relevance analysis (Current & future impact)
FIG. 15 Risk associated with outsourcing services
FIG. 16 New technologies adopted by CMOs for fill/finish
FIG. 17 Major CMO consolidation deals in 2022
FIG. 18 CMOs are trading at strong EV/EBITDA multiples
FIG. 19 Trends in biopharmaceutical industry
FIG. 20 Steps in the estimation of capital investment and operating costs
FIG. 21 Capital expenditure comparison between SUT and SS-based biologic manufacturing
FIG. 22 Operating expense comparison between SUT and SS-based biologic manufacturing
FIG. 23 Operating expense-labor comparison between SUT and SS-based biologic manufacturing
FIG. 24 Distribution, average USD cost per gram for recombinant protein, 2022
FIG. 25 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 26 Porter’s Five Forces Analysis
FIG. 27 U.S. biopharmaceuticals contract manufacturing market: Source outlook key takeaways
FIG. 28 U.S. biopharmaceuticals contract manufacturing market: Source movement analysis
FIG. 29 U.S. mammalian source market, 2018 - 2030 (USD Million)
FIG. 30 U.S. non-mammalian source market, 2018 - 2030 (USD Million)
FIG. 31 U.S. biopharmaceuticals contract manufacturing market: Contract manufacturing service type outlook key takeaways
FIG. 32 U.S. biopharmaceuticals contract manufacturing market: Contract manufacturing service type movement analysis
FIG. 33 U.S. process development market, 2018 - 2030 (USD Million)
FIG. 34 U.S. downstream processing market, 2018 - 2030 (USD Million)
FIG. 35 U.S. upstream processing market, 2018 - 2030 (USD Million)
FIG. 36 U.S. fill & finish operations market, 2018 - 2030 (USD Million)
FIG. 37 U.S. analytical & QC studies market, 2018 - 2030 (USD Million)
FIG. 38 U.S. contract packaging market, 2018 - 2030 (USD Million)
FIG. 39 U.S. biopharmaceuticals contract manufacturing market: Product outlook key takeaways
FIG. 40 U.S. biopharmaceuticals contract manufacturing market: Product movement analysis
FIG. 41 U.S. biologics market, 2018 - 2030 (USD Million)
FIG. 43 Share of MAb-related R&D programs at different development phases, 2022
FIG. 44 U.S. monoclonal antibodies market, 2018 - 2030 (USD Million)
FIG. 45 Comparison of R&D pipeline expansion for recombinant products, 2020-2022
FIG. 46 U.S. recombinant proteins market, 2018 - 2030 (USD Million)
FIG. 47 U.S. vaccines market, 2018 - 2030 (USD Million)
FIG. 48 U.S. antisense, RNAi, &molecular therapy market, 2018 - 2030 (USD Million)
FIG. 49 U.S. other product market, 2018 - 2030 (USD Million)
FIG. 50 U.S. biosimilar market, 2018 - 2030 (USD Million)
FIG. 87 Strategy framework
FIG. 88 Participant categorization